BridgeBio Pharma (BBIO) Receivables (2021 - 2026)

BridgeBio Pharma has reported Receivables for 6 years, with the latest figure at $205.2 million in Q1 2026.

• Quarterly Receivables rose 78.05% year-over-year to $205.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $205.2 million (up 78.05% YoY) and the FY2025 annual result came in at $139.4 million, up 2853.07% from the prior year.
• Receivables grew to $205.2 million in Q1 2026 per BBIO's latest filing, from $139.4 million in the prior quarter.
• Over five years, Receivables peaked at $335.9 million in Q1 2024 and troughed at $678000.0 in Q3 2024.
• A 5-year average of $68.7 million and a median of $22.8 million in 2022 frame the typical range for Receivables.
• The sharpest annual moves came in 2024 and 2025: Receivables sank 94.31% in 2024, then surged 17085.55% in 2025.
• Over 5 years, Receivables stood at $33.9 million in 2022, then tumbled by 92.18% to $2.7 million in 2023, then soared by 78.12% to $4.7 million in 2024, then jumped by 2853.07% to $139.4 million in 2025, then jumped by 47.17% to $205.2 million in 2026.
• According to Business Quant data, Receivables over the past three periods registered $205.2 million, $139.4 million, and $116.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.